AstraZeneca funds 'phenomenal' deal despite Brexit vol
GlobalCapital, is part of the Delinian Group, DELINIAN (GLOBALCAPITAL) LIMITED, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 15236213
Copyright © DELINIAN (GLOBALCAPITAL) LIMITED and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
EquityABBs-Block Trades

AstraZeneca funds 'phenomenal' deal despite Brexit vol


AstraZeneca, the British-Swedish pharmaceuticals giant, has priced a historic £2.7bn accelerated transaction ($3.5bn) to fund a transformational oncology collaboration. But sources close to the deal say that execution was complicated by Brexit drama last Friday.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login
Gift this article